AtaiBeckley Inc

May is #MentalHealthAwarenessMonth. It’s a time for recognition of how far we’ve come and a reminder of how much more progress is needed. Over 1B people globally live with mental health conditions, many without access to effective, durable care. Addressing this unmet need requires collaboration. At AtaiBeckley, we are proud to work together across science and patient impact. Because good days shouldn’t be the exception — they should be the goal. Learn more: ataibeckley.com/our-work/patie… #MoreGoodDays #MentalHealthMatters

Happening today at the Needham Virtual Psychedelics Forum: our CEO @SriniGRao joins a panel on clinical risk, regulatory pathways, and commercial scalability for transformative mental health therapies. Webcast link: ir.ataibeckley.com/events/event-d… $ATAI #BPL003 #CreatingBreakthroughsInMentalHealth

AtaiBeckley receives the Silver Award in @OVIDHealth’s 2026 Patient Participant Index, recognizing our collaboration with @PsyPAN_org to embed participant voice and peer support into psychedelic clinical research. ir.ataibeckley.com/news-releases/… $ATAI #PatientPartnership #CreatingBreakthroughsinMentalHealth #MentalHealthInnovation #PatientVoice

Thankful to take part in this thoughtful @BioSpace discussion on the potential opportunities - and real implications - of last week's Executive Order on psychedelic medicine. Policy signals matter, and how they’re implemented will shape innovation, timelines, and ultimately patient access to new options for difficult‑to‑treat neuropsychiatric conditions. Link: biospace.com/drug-developme…

Today we announced the full Phase 2a results for EMP‑01 (oral R‑MDMA) in adults with Social Anxiety Disorder. Results from the study (N=70) showed clinically meaningful and consistent improvements across clinician-rated symptoms, patient-reported experience, and real-world behavioral outcomes. Read the full announcement: ir.ataibeckley.com/news-releases/… $ATAI #EMP01 #SocialAnxietyDisorder #Biotech #MentalHealth

A landmark moment for mental health and psychedelics. Today's Executive Order potentially accelerates much needed therapies to patients, including our portfolio of next-generation, rapid-acting psychedelics. whitehouse.gov/presidential-a… $ATAI #MentalHealth #Biotech #CreatingBreakthroughsinMentalHeath

Spotify: open.spotify.com/episode/7smdy5… Apple: podcasts.apple.com/us/podcast/epi… Youtube: youtu.be/P-xAc2uRvx0?si…

🎙️Our CEO Srinivas Rao joined Max Brennan, MSc on The BioHub – by Avetix podcast for a wide‑ranging conversation on AtaiBeckley’s origin, evolution, and mission to tackle one of the greatest unmet needs in mental health. From Srini’s journey from CSO to CEO, to the science behind our pipeline - including BPL‑003, EMP‑01 and VLS‑01 - it’s a must‑listen. 🎧 Full episode linked below. ⬇️

AtaiBeckley will participate in the 25th Annual Needham Virtual Healthcare Conference (Apr 13 -16) and the Needham Virtual Psychedelics Forum (Apr 27). ir.ataibeckley.com/news-releases/… $ATAI #BPL003 #CreatingBreakthroughsInMentalHealth

What does it take to design psychedelic therapies that can work at scale for treatment‑resistant depression? In a new Drug Discovery World piece, our CMO Kevin Craig explores the clinical and operational challenges shaping the next phase of the field. 🔗ddw-online.com/designing-scal… #TreatmentResistantDepression #PsychedelicMedicine #MentalHealth #ClinicalResearch

Initiation of Phase 3 studies on track for Q2 2026 following recent FDA End-of-Phase 2 alignment. Read the open-access paper: doi.org/10.1007/s40263… $ATAI #BPL003 #TreatmentResistantDepression #PsychedelicMedicine #ClinicalTrials #Biotech #MentalHealth

(2/3) Dr Kevin Craig, Chief Medical Officer at AtaiBeckley said: “This study provides the first Phase 2a evidence that BPL‑003 can be administered alongside SSRIs without compromising efficacy or safety, a meaningful advance given that many TRD patients remain on chronic SSRI therapy.” $ATAI #BPL003 #TreatmentResistantDepression #PsychedelicMedicine #ClinicalTrials #Biotech #MentalHealth

(1/3) For HCPs, investors & media. New Phase 2a data published in CNS Drugs shows that a single dose of BPL-003 produced a rapid, durable antidepressant response, with a favourable safety profile, in patients with TRD who were on SSRIs. ir.ataibeckley.com/news-releases/… $ATAI #BPL003 #TreatmentResistantDepression #PsychedelicMedicine #ClinicalTrials #Biotech #MentalHealth

Today is #WorldHealthDay. This year’s theme - Together for health. Stand with science - celebrates the power of collaboration and evidence to improve health for people and planet. Thank you to our AtaiBeckley colleagues who shared what health means to them. #TogetherForHealth #StandWithScience #HealthAndWellbeing #AtaiBeckley

AtaiBeckley has been added to S&P Total Market Index, S&P Completion Index and CRSP® U.S. benchmark indices. Strengthens visibility across major U.S. equity benchmarks that underpin more than $3 trillion in passive AUM and builds on our inclusion in the Nasdaq Biotechnology Index in December 2025. BPL-003 Phase 3 program remains on track to initiate in Q2 2026, and topline data from the VLS-01 Phase 2b study are expected in H2 2026. ir.ataibeckley.com/news-releases/… $ATAI #SmallCapBiotech #IndexInclusion #BPL003 #TRD #Biotech

Positive new Phase 2a data for BPL‑003 in #TRD have been published in the Journal of Psychopharmacology, strengthening the evidence base for the compound ahead of Phase 3 initiation in Q2’26. Read more: ir.ataibeckley.com/news-releases/… $ATAI #BPL003 #TreatmentResistantDepression #Biotecg

Thank you to everyone who joined us for our Virtual Investor Day on Friday March 6. The event featured clinical, regulatory and operational updates from members of our executive team as well as an engaging roundtable discussion on the unmet needs in mental health with external key opinion leaders. If you missed it, or would like a reminder of what we covered, we have issued a summary of the key highlights below: ir.ataibeckley.com/news-releases/… #AtaiBeckley #Biotechnology #BreakthroughsinMentalHealth

Today’s the day: the AtaiBeckley Virtual Investor Day begins shortly from 9:00 a.m. - 12:00 p.m. ET. Tune in to hear directly from our executive team and key opinion leaders as we showcase progress across our clinical pipeline to advance rapid‑acting, durable and convenient mental health treatments. Join the live webcast: app.webinar.net/7e5Jn1zYlXj #InvestorDay #AtaiBeckley #Biotech #MentalHealthInnovation

AtaiBeckley reports Q4 & FY 2025 financial results and company updates: - Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration - On-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2 2026 - Exploratory Phase 2a trial of EMP-01 in Social Anxiety Disorder met its primary safety and tolerability objective and demonstrated clinically meaningful improvements across key efficacy measures - Cash runway through the planned early-2029 topline readouts from both Phase 3 pivotal studies - Virtual Investor Day scheduled for March 6, 2026 Full update: ir.ataibeckley.com/news-releases/… #Biotech #MentalHealthInnovation #AtaiBeckley

For #Investors and #Media: Following the announcement of positive topline results from our exploratory, placebo-controlled Phase 2a trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder (SAD), our CEO Dr @SriniGRao spoke to Steve Darling from @proactive_x. During the interview they discussed the data in more detail, including the unmet need in SAD, the need for new innovation and how EMP-01 has the potential to be a transformative development for patients with this condition. Listen below. #MentalHealthInnovation #ClinicalTrials #SocialAnxietyDisorder #Biotechnology #AtaiBeckley